[Federal Register Volume 77, Number 87 (Friday, May 4, 2012)]
[Notices]
[Page 26585]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-10767]


=======================================================================
-----------------------------------------------------------------------

REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION

[BAC 416404]


Annual Public Meeting

ACTION: Notice of annual meeting.

-----------------------------------------------------------------------

SUMMARY: The Reagan-Udall Foundation for the Food and Drug 
Administration (FDA), which was created by Title VI of the Food and 
Drug Amendments of 2007, is announcing an annual open public meeting. 
The Foundation will provide an overview of its history, project 
updates, as well as projected activities going forward.

DATES: The open public meeting will be held on May 23, 2012, from 10 
a.m. until 12 noon. Interested persons may sign up to attend in person 
and/or make comments at the meeting or submit written comments by 
visiting http://www.ReaganUdall.org on or before May 17, 2012. Oral 
comments from the public will be scheduled between approximately 11 
a.m. and 12 p.m. Time allotted for each registrant will be 3 minutes. 
The contact person will notify interested persons regarding their 
request to speak by May 23, 2012. Written comments are encouraged. 
Those individuals interested in making formal comments should notify 
the contact person and submit a brief statement of the general nature 
of the comments they wish to present. Written comments are encouraged 
through May 25, 2012.
    Location: West Policy Center, 1909 K St. NW., Suite 730, 
Washington, DC 20006.

FOR FURTHER INFORMATION CONTACT: Jane Reese-Coulbourne, Reagan-Udall 
Foundation for the FDA, 202 828-1205, [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    The Reagan-Udall Foundation for the FDA (the Foundation) is an 
independent 501(c)(3) not-for-profit, organization created by Congress 
to advance the mission of FDA to modernize medical, veterinary, food, 
food ingredient, and cosmetic product development; accelerate 
innovation, and enhance product safety. With the ultimate goal of 
improving public health, the Foundation provides a unique opportunity 
for different sectors (FDA, patient groups, academia, other government 
entities, and industry) to work together in a transparent way to create 
exciting new research projects to advance regulatory science.
    The Foundation acts as a neutral third party to establish novel, 
scientific collaborations. Much like any other independently developed 
information, FDA evaluates the scientific information from these 
collaborations to determine how Reagan-Udall Foundation projects can 
help the agency to fulfill its mission.
    The Foundation has announced initial projects including: An 
evaluation of a systems biology approach to preclinical safety testing; 
new ways to develop tuberculosis (TB) multi-drug regimens; and pilot 
fellowship programs in the areas of safety surveillance, large scale 
data analysis, and toxicology. The Foundation seeks comments on these 
and other potential topics for future activities.

II. Agenda

    The Foundation will be providing an overview of its history, 
project updates, as well as projected activities going forward. Find 
the Meeting Agenda at http://www.ReaganUdall.org.

    Dated: April 30, 2012.
Jane Reese-Coulbourne,
Executive Director, Reagan-Udall Foundation for the FDA.
[FR Doc. 2012-10767 Filed 5-3-12; 8:45 am]
BILLING CODE 4164-04-P